Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Dow
AstraZeneca
Colorcon
Medtronic
Mallinckrodt

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Panitumumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Panitumumab: Patents, clinical trial progress, indications

Panitumumab is an investigational drug.

There have been 207 clinical trials for Panitumumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Adenocarcinoma, and Carcinoma, Squamous Cell. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and Takeda.

There are two hundred and sixty-six US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Panitumumab
TitleSponsorPhase
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical ProceduresStanford UniversityPhase 1/Phase 2
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal CancerTesaro, Inc.Phase 2
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal CancerEmory UniversityPhase 2

See all Panitumumab clinical trials

Clinical Trial Summary for Panitumumab

Top disease conditions for Panitumumab
Top clinical trial sponsors for Panitumumab

See all Panitumumab clinical trials

US Patents for Panitumumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Panitumumab   Start Trial Trilayer coated pharmaceutical packaging SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)   Start Trial
Panitumumab   Start Trial Methods of enhancing antibody-dependent cellular cytotoxicity VentiRx Pharmaceuticals, Inc. (Seattle, WA)   Start Trial
Panitumumab   Start Trial Encapsulated agents and methods of making and using thereof University of Georgia Research Foundation, Inc. (Athens, GA)   Start Trial
Panitumumab   Start Trial High resolution melting analysis as a prescreening tool Roche Molecular Systems, Inc. (Pleasanton, CA)   Start Trial
Panitumumab   Start Trial K-ras mutations and anti-EGFr antibody therapy AMGEN, INC (Thousand Oaks, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Panitumumab

Drugname Country Document Number Estimated Expiration Related US Patent
Panitumumab Argentina 082615 2030-08-09   Start Trial
Panitumumab Australia 2010249031 2030-05-12   Start Trial
Panitumumab Australia 2010249033 2030-05-12   Start Trial
Panitumumab Australia 2011252925 2030-05-12   Start Trial
Panitumumab Australia 2012318242 2030-05-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Boehringer Ingelheim
Moodys
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.